Novel anti-neuroinflammatory pyranone-carbamate derivatives as selective butyrylcholinesterase inhibitors for treating Alzheimer’s disease
Journal of Enzyme Inhibition and Medicinal Chemistry · 31.12.2024 · 39 (1)
DOI: 10.1080/14756366.2024.2313682 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Enzyme Inhibition and Medicinal Chemistry, online erschienen am 16.02.2024. Verfasst von Chuanyu Yu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, School of Pharmacy, Fujian Medical University, Fuzhou, Fujian Province, China. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Fujian Province, Talented Scholars of Fujian Medical University.
Themen: Demenz
Abstract (Originalsprache)
Butyrylcholinesterase (BuChE) and neuroinflammation have recently emerged as promising therapeutic directions for Alzheimer's disease (AD). Herein, we synthesised 19 novel pyranone-carbamate derivatives and evaluated their activities against cholinesterases and neuroinflammation. The optimal compound 7p exhibited balanced BuChE inhibitory activity (eqBuChE IC50 = 4.68 nM; huBuChE IC50 = 9.12 nM) and anti-neuroinflammatory activity (NO inhibition = 28.82% at 10 μM, comparable to hydrocortisone). Enzyme kinetic and docking studies confirmed compound 7p was a mix-type BuChE inhibitor. Additionally, compound 7p displayed favourable drug-likeness properties in silico prediction, and exhibited high BBB permeability in the PAMPA-BBB assay. Compound 7p had good safety in vivo as verified by an acute toxicity assay (LD50 > 1000 mg/kg). Most importantly, compound 7p effectively mitigated cognitive and memory impairments in the scopolamine-induced mouse model, showing comparable effects to Rivastigmine. Therefore, we envisioned that compound 7p could serve as a promising lead compound for treating AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, School of Pharmacy, Fujian Medical University, Fuzhou, Fujian Province, China.
- Fujian Key Laboratory of Drug Target Discovery and Structural and Functional Research, Fujian Medical University, Fuzhou, Fujian Province, China.
- Department of Pharmaceutical Analysis, School of Pharmacy, Fujian Medical University, Fuzhou, Fujian Province, China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Fujian Province
- Talented Scholars of Fujian Medical University
Zitieren
APA
Yu, C., Liu, X., Ma, B., Xu, J., Chen, Y., Dai, C., Peng, H., & Zha, D. (2024). Novel anti-neuroinflammatory pyranone-carbamate derivatives as selective butyrylcholinesterase inhibitors for treating Alzheimer’s disease. Journal of Enzyme Inhibition and Medicinal Chemistry, 39(1). https://doi.org/10.1080/14756366.2024.2313682
Vancouver
Yu C, Liu X, Ma B, Xu J, Chen Y, Dai C, et al. Novel anti-neuroinflammatory pyranone-carbamate derivatives as selective butyrylcholinesterase inhibitors for treating Alzheimer’s disease. Journal of Enzyme Inhibition and Medicinal Chemistry. 2024;39(1). doi:10.1080/14756366.2024.2313682
BibTeX
@article{Yu2024,
author = {Yu, Chuanyu and Liu, Xueyan and Ma, Bingxiang and Xu, Jiexin and Chen, Yiquan and Dai, Chaoxian and Peng, Huaping and Zha, Daijun},
title = {Novel anti-neuroinflammatory pyranone-carbamate derivatives as selective butyrylcholinesterase inhibitors for treating Alzheimer’s disease},
journal = {Journal of Enzyme Inhibition and Medicinal Chemistry},
year = {2024},
volume = {39},
number = {1},
doi = {10.1080/14756366.2024.2313682}
}
EUVIMED